Amro Albanna (00:00): Okay. Here we go. Welcome, everyone. Thank you for joining us in our weekly updates. We thought this would be a great idea for us to communicate with our stakeholders. I know there is so many things

Amro Albanna (00:00):

Okay. Here we go. Welcome, everyone. Thank you for joining us in our

weekly updates. We thought this would be a great idea for us to communicate with our stakeholders. I know there is so many things happening

with Aditxt, and as we move forward, we want to make sure that we deploy whatever mechanisms we have to keep you updated on what's going

on, inclusive of answering some of the questions that we have been receiving from you.

With that said, Jeff, thank you again for agreeing to facilitate this

call. And Saundra, very much appreciate you joining us. You're going to be the star of the show today.

Saundra Pelletier, CEO, Evofem (00:41):

Amro Albanna (00:42):

And we would love to really get it started. So look, we've done these

things a few times and I think it's important for us to know that not everybody know who we are and what we do. And maybe we'll start

with you, Jeff, with a quick intro and we'll take it from there.

Jeff Ramson, CEO PCG Advisory (00:58):

Sure, sure. Okay. So I'm Jeff Ramson. I'm the CEO of PCG Advisory,

a long time associate of Amro's and working very closely with Amro and the team at Aditxt on communications and making sure that we're

getting this ever expanding message out into the marketplace and to the right people in the right way.

Amro Albanna (01:18):

Great. Thank you, Jeff. Saundra?

Saundra Pelletier, CEO, Evofem (01:21):

I am Saundra Pelletier, the CEO of Evofem Biosciences. I have spent

my entire career focused on women's health, women from puberty through menopause. And really understanding what unmet needs exist, but

then more importantly, how to provide solutions that will change the quality of life for women. So I'm really excited to be here today

to talk more about that.

Amro Albanna (01:43):

Appreciate it, Saundra. And again, thank you for joining us. Look,

we want to make sure that these weekly sessions are on point, informative, and productive. So what we're going to discuss today is, number

one, why Evofem? Why are we continuing to work together? Because I think that's really important, before we get into all the tactics,

special meetings, what we're trying to do, ultimately, why is Saundra and her team interested in moving forward? Why I and my team are

interested in moving forward.

And then we will share with you the status of where we are, the plan

moving forward. And we'll ask questions, some of the questions at least that came through. And Jeff, I know that obviously you receive

questions every single day. You can fire away as we move forward.

So that said, let's really begin with women's health. What is the challenge

with women's health, Saundra? And why Evofem? And why you think Evofem is truly in a position to contribute to women's health in a meaningful

Saundra Pelletier, CEO, Evofem (02:48):

So our mandate at Evofem has always been to be a global enterprise,

really delivering on unmet needs. Recognizing that the US market is the most profitable, but also recognizing that there is a lot of money

to be made ex-US, while still delivering for women. The bottom line is women don't need more choices, we need better ones.

So just to start with Phexxi, our small little company was the only

company that was willing to take the kind of risk to bring the only FDA-approved non-hormonal birth control to market that women use on

demand. Let tell you why that matters. 23 million women will not use hormones. 23 million women include a lot of young women who say,

"I am so worried about infertility. What is my ability to get pregnant going to be if I ingest a synthetic hormone in my body every

Women don't have sex every day. COVID made women wake up and say, "I

don't feel as good as I should. I need to look at everything I'm ingesting in my body." And I can tell you a lot of those women said,

"It's my hormonal birth control that's making me not feel great."

So we were the only company that was willing to say, "There's

45 birth control pills on the market." Women can get a synthetic hormone in a pill, in a patch, in an IUD. Well, what about something

on demand, like men have had condoms? Phexxi is a true innovation.

Now, we wish more people knew about it. We launched during COVID. We've

had a very, very difficult time building momentum because we've needed a growth partner, a strategic growth partner, which you're going

to hear more about today. That's why we remain committed to our partnership with Aditxt.

Secondly, we were able to bring in a second FDA-approved product, SOLOSEC.

SOLOSEC is for yet another unmet need, bacterial vaginosis and trichomoniasis. In the United States, 21 million women have BV, 3.7 million

women have tric. Guess why SOLOSEC matters? It's an innovation because it's one and done. Women are being asked now to take something

twice a day for seven to 14 days. When they are having pain, when they are having discharge, when they have the shame of these terrible,

terrible situations, SOLOSEC is a packet of granules. You put it in applesauce, pudding, or yogurt and that's it. It's a silver bullet,

one and done. Truly different, not another me too product in a crowded category.

So we have two FDA-approved products. The other thing that we care

about is looking at what are these things that impact women. Endometriosis, it is absolutely debilitating. 6.5 million women in the US

have endometriosis, but it is the number one cause of infertility. But the most significant thing is early detection not only slows the

progression but can halt the progression. Another Aditxt company, Pearsanta, is developing this early detection test for endometriosis.

It will be game-changing for women. It will continue to show physicians and women that Evofem is the kind of company that delivers real

solutions that are better, not just me too things in crowded categories.

Big pharma should have leaned in and brought a product like Phexxi

to market, but they didn't because they thought there's enough choices for women. We don't need to do something hard like bring a brand

new chemical entity to market. We'll just deliver the same hormones in a different way.

So Aditxt has recognized that Evofem is willing to do hard things for

the right reasons, and we're very proud of that. A lot of people have taken their companies in other directions and shut their doors during

COVID. We have shown that we are resilient, that we have grit, but partnership is what we need. So that's why we're excited today to have

these two FDA-approved assets and a forthcoming other opportunity in our bank for endometriosis from Pearsanta.

Amro Albanna (06:52):

You certainly have been a fighter, Saundra. And I mean to reiterate

what you said twice, look, you have an FDA product in the prevention category with Phexxi. You have an FDA-approved product in the treatment

category with SOLOSEC. And soon, second half of this year, with what Pearsanta, our other Aditxt company, is working on with endometriosis,

you will have another or a third product in the monitoring and diagnosis category.

So that said, the opportunity obviously is, in the US and globally,

the opportunity exists for Evofem. It is the opportunity to impact millions of women all around the world. I think that's a fair statement

and that's what we see.

And that really brings us to Aditxt as a model. Our model is to identify

companies that are truly positioned to capture a global opportunity, to make impactful difference, to address some of our most pressing

health challenges in the world. And once we identify the company, we bring them in and we become a strategic partner in whatever form,

whatever factor that takes, that will become a strategic partner oriented by their growth. That's our DNA, no pun intended. That's what

we want to see, that these innovative companies become successful, because their success will mean the success for all stakeholders. With

the ultimate goal of launching them globally, such as an IPO listing, where they become independent out there in the world, similar to

what we're doing with Pearsanta.

And look, we are a small company ourselves and we have been fighting

the battles along the way, especially the last couple years to three years. So that's really why we're here and that's why we continue

to work with Saundra and her team. And that's why Jeff has been part of the journey and our team has been part of the journey throughout.

So let's talk about where we are. I think our transaction was December

2023, I believe it was. So now it's longer than a year and it's been a long time, we know. We know it's been a long time. But the fact

that we're both here on this call together, I hope should say a lot, that we're still here, our team is still moving forward.

So let's talk about the status. Right now, and obviously, Saundra,

from your point of view, you can add whatever you see appropriate here. Number one, we currently have an existing agreement in place that

basically the outside date was back end of January. The agreement continues to be in effect. And either company, either one of us can

terminate the agreement. That's the fact. It hasn't been terminated. I haven't done it, Saundra hasn't done it. That's why we're still

working together. But that's the current status.

As we move forward, the question is what's next? So given what we just

shared with you as far as why Evofem, why women's health, and why Aditxt, question is how do we move forward? And the best way to make

it clear, the key, I believe, that must be addressed before we can move forward in a meaningful way, is we must address the senior creditor

that Evofem has. That's number one, right? We have to address it, we have to pay it off, we have to have someone else assume it. Whatever